MedPath

Diabetes Treatment by Glucobay® With a Special Therapeutic View to Chosen Patient Groups

Phase 4
Registration Number
CTRI/2010/091/000241
Lead Sponsor
Bayer Schering Pharma AG
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
16000
Inclusion Criteria

All patients with untreated or pretreated diabetes mellitus type 2/ IGT can be included into the study.
No Glucobay® intake within the last 3 months before documentation of initial visit

Exclusion Criteria

contraindication stated in the local Glucobay® product information; warnings and precautions
must be considered.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath